JGJosé Gerardo González-González

José Gerardo González-González

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Gerardo González-González has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study

    by Niharika Samala, José González-González, Robert A Jenders, Monika Sarkar, Raymundo Garcia Reza, Fabian Rodas, Mark Kipnes, Efraín Montaño González, Heather G. Huddleston, Taufik Momin, et al.

    Background and Aims: Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction–associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar, a novel peroxisome proliferator–activated receptors α/γ agonist, for the treatment of hepatic steatosis in women with PCOS and MASLD. Methods: In this multicenter, randomized, double-blind, placebo-controlled phase 2A trial, 60 women (18–45 y) with PCOS and MASLD were randomized 1:1 to either saroglitazar 4 mg or placebo for 24 weeks. The primary endpoint was relative (percent) change in hepatic fat content, measured by MRI proton density fat fraction. Primary analysis was performed in the per-protocol population (saroglitazar: 25; placebo: 23). Results: Participants in the saroglitazar group showed a significant reduction in percent hepatic fat content at 24 weeks from baseline compared to placebo ([least squares mean±SE]: −14.81±5.52 vs. 1.96±5.75, p =0.041). When controlled for baseline HbA1c imbalance, the beneficial effect of saroglitazar was more pronounced ([least squares mean±SE]: −18.93±4.83 vs. 6.43±5.04, p p =0.025). Saroglitazar also significantly reduced aminotransferase levels, lipid parameters, and the FibroScan AST score. Adverse events were comparable between the groups, and none were serious. One pregnancy in the saroglitazar arm resulted in uneventful maternal and neonatal outcomes. Conclusions: In women with PCOS and MASLD, saroglitazar significantly improved hepatic steatosis, liver enzymes, lipid profile, and FibroScan AST score. These findings support further evaluation of saroglitazar in larger studies in women with PCOS.

  • Open Access

    Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review

    by Daniela C González-Cruz, Mariano Garcia-Campa, Pablo José Moreno-Peña, Andres Avalos-Bishop, Dulce María Manzanares-Gallegos, Fernanda M Garcia-Garcia, Jan Alejandro Montiel Labastida, José Gerardo González-González, Arnav Agarwal, Veena Manja, et al.

  • Genetic polymorphisms in the response to NB ‐ UVB phototherapy in vitiligo: A prospective study

    by Anabell Andrea Lima‐Galindo, Mauricio Andrés Salinas‐Santander, Jorge Ocampo‐Garza, Miguel Bonifacio Favela‐Gálvez, Alejandra Brown‐Herrera, José Gerardo González‐González, Jorge Martín Llaca‐Díaz, Adriana Sánchez‐García, Jorge Ocampo‐Candiani


  • Open Access

    Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

    by Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, et al.

    Aims: To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods: This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D, Body Mass Index ≥27 kg/m 2 , and glycated haemoglobin (HbA1c) 7.0–10.0%. Participants were randomized (1:2:1) to once‐daily CT‐868 1.75 mg, 4.0 mg, or placebo. Due to COVID‐19‐related CT‐868 supply constraints, some participants randomized to 4.0 mg received 3.25 mg maximum and were analysed as a separate dose arm. The primary endpoint was change from baseline in HbA1c at W26. Secondary endpoints included changes from baseline to W26 in fasting glucose, 7‐point self‐monitored blood glucose (SMBG), body weight, lipids and the occurrence of adverse events (AEs). Results: Overall, 103 participants were enrolled (CT‐868 1.75 mg, n = 26; 3.25 mg, n = 18; 4.0 mg, n = 32; placebo, n = 27). Clinically meaningful and statistically significant improvements in HbA1c were observed with CT‐868 at W26 (−1.61 to −2.24%‐points vs. placebo; all p < 0.001). Body weight was modestly reduced with CT‐868 4.0 mg at W26 (−2.9% vs. placebo, p < 0.001). CT‐868 improved fasting glucose, SMBG, and most lipid parameters vs. placebo. AEs were mostly mild/moderate. No participants experienced hypoglycaemia. Conclusions: CT‐868 1.75 to 4.0 mg yielded robust, clinically meaningful decreases in HbA1c, supporting potent glycaemic‐lowering effects and improved key lipid parameters in participants with overweight/obesity and T2D, despite modest weight loss. CT‐868 was well tolerated, supporting future investigation of higher doses to maximize weight loss.


  • Open Access

    Acanthosis Nigricans as a Clinical Risk Marker for Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Adriana Sánchez-García, María Eugenia Penados-Ovalle, René Rodríguez-Gutiérrez, Fernando Díaz-González Colmeneros, José Gerardo González-González

    Background: Despite the association of insulin resistance (IR) in the pathophysiology of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), few studies have evaluated the utility of acanthosis nigricans (AN) as a clinical predictor for this condition. Thus, we aimed to determine the role of AN as a risk factor and clinical predictor of MASLD. Methods: This cross-sectional study conducted a comprehensive clinical history and physical examination. The presence of acanthosis nigricans was assessed in the neck, elbows, axillae, and knuckles. Liver biochemical parameters were measured, hepatic fat was analyzed using the controlled attenuation parameter (CAP), while hepatic stiffness was evaluated in kilopascals (kPA) with the FibrosScan 530 Compact and Smart Exam software. Multiple analyses were performed to determine the relationship between acanthosis nigricans and MASLD. Results: We recruited 251 adult participants. The mean BMI was 29.9 ± 7.3 kg/m 2 , including 40.2% of participants with obesity and 63.7% with AN. Transient elastography evaluation resulted in 65.7% and 6% participants with hepatic steatosis (S3, 48.6%) and fibrosis, respectively. A non-adjusted (OR 2.63, 95% CI 1.57-4.52) and adjusted model (OR 1.97, 95% CI 0.95-4.12) were determined for AN as a risk factor for liver steatosis. Furthermore, the presence of AN in knuckles resulted in an association to predict liver steatosis (OR 2.09, 95% CI 1.01-4.35), while a multivariate analysis indicated that AN predicts a higher steatosis grade (S2 OR = 6.58, CI 95% 1.18-36.53; S3 OR = 2.36, CI 95% 1.04-5.3). Conclusions: Acanthosis nigricans demonstrated to predict a higher steatosis grade in adults with overweight and obesity. Our study supports the clinical applicability of AN as a screening tool for MASLD to identify high-risk subjects in resource-limited settings. Additional studies are needed to define alternative diagnostic tools for the early identification of metabolic risk factors in populations with specific clinical or demographic characteristics.


  • Open Access

    The safety of BCG revaccination in the context of COVID-19

    by Adriana Sánchez-García, Reyes Támez-Guerra, Gerardo González-Saldivar, René Rodríguez-Gutiérrez, Luz Adriana Ramírez-García, Francisco J. Barrera, José Gerardo González-González

    The bacille Calmette-Guérin (BCG) vaccine is administered in many countries as part of their vaccination schedules. Epidemiologic studies have suggested a possible benefit of this vaccine in the context of the COVID-19 pandemic and other respiratory infections. We aimed to assess the safety of this intervention in BCG-primed adults. Adult health care workers (n = 451) received a single intradermal application of the BCG vaccine (Tokyo 172 strain) in the deltoid region of the right arm. Follow-up (30 days) calls and clinical inspections were guided using a standardized data sheet to assess local and systemic reactions. Early local reactions were common at 24 h and 7 days, such as erythema (74.9%, 69.2%), induration (55.7%, 59%), a papule (53.4%, 47.7%), and edema (48.3%, 38.1). Local symptoms (pruritus 44.8%, heat 16.2%, and pain 34.8%) were less frequent at day 7. Late expected reactions (14 and 30 days) included the formation of crusts (39.6% and 63.9%), a pustule (36.6% and 17%), or ulcers (28.8% and 17.7%). Severe reactions were limited to subcutaneous abscesses (2%) and lymphadenitis (<1%).


  • Open Access

    Retinal Microvascular Density and Perfusion during an Insulin-Induced Hypoglycemia Episode: A Warning Call

    by Gerardo González-Saldivar, José Gerardo González-González, David Robert Chow, Jesús Mohamed-Hamsho, Jesús Hernan González-Cortés, Adriana Sánchez-García, René Rodríguez-Gutiérrez

    Aim. To evaluate retinal vascular perfusion and density by optical coherence tomography angiography (OCTA) before, during, and after hypoglycemia in individuals with diabetes mellitus with or without diabetic retinopathy (DR). Methods. A focused clinical history was performed, followed by an ophthalmological examination to document retinopathy status. OCTA was performed at baseline, at hypoglycemia, and at glucose normalization. Eye tracking and eye alignment devices on the platform were used to obtain a macular thickness cube (512×128) and vascular perfusion and density protocols of 3×3mm. Retinal vascular reactivity was analyzed with superficial plexus vascular perfusion and density protocols on OCTA. Results. Fifty-two participants encompassing 97 eyes fulfilled the eligibility criteria. Their mean age was 42.9±15.1years (range, 22 to 65), and 20 (38.2) were men. We found a statistically significant difference in vascular perfusion and density when comparing all groups at baseline. The controls had higher vascular perfusion and density values than the cases. Vascular perfusion and density were significantly reduced in all groups during the hypoglycemia episode, except for vascular density in DR cases. Conclusion. Acute hypoglycemia significantly alters the retinal vascularity in DM patients with and without DR, suggesting that repeated episodes of acute hypoglycemia could exacerbate retinopathy in the long term.


  • Open Access

    Low-Dose ACTH Stimulation Test in Obesity: A Randomized Dose Assessment

    by Leonardo G. Mancillas-Adame, Adriana Sánchez-García, Rene Rodriguez-Gutierrez, Camilo Gonzalez-Velazquez, Fernando Javier Lavalle-Gonzalez, Jorge A. Zuñiga-Hernandez, Adriana Gabriela Rios-Ortega, José Gerardo González-González

    Background. The short cosyntropin test is widely used for adrenal insufficiency screening and diagnosis. Lower cosyntropin doses may have greater sensitivity vs. the standard dose in detecting adrenal dysfunction. Obesity and overweight are increasing, impacting the clinical presentation of some diseases. Currently more than 50% of the subjects diagnosed with autoimmune adrenal insufficiency have a BMI greater than 25, and hence individuals living with overweight and obesity are more frequently requiring evaluation of the adrenal cortical function. Fixed-dose cosyntropin stimulation may not be appropriate for individuals with obesity. Objective. The primary objective was to compare cortisol response to a weight-adapted cosyntropin dose vs. a fixed low dose (1 µg) and a more physiologically fixed dose (10 µg). Methods. Twenty individuals with obesity and 20 age-matched healthy controls underwent in a randomized sequence at least one-week apart, to the The short cosyntropin test with three different doses, 0.2 µg/kg of body weight, 1 or 10 µg fixed dose stimuli. The assessment and data analysis were blinded to the individual and the investigator. Results. Cortisol response was reduced in the group with obesity with the 1 µg fixed dose stimuli at 30 minutes (median, IQR) 649.6 µg, 567.3–738.4 µg for the control group vs. 568.6 µg, 528.4–623.13 µg, ; there was a lower cortisol peak at 60′ in all the three evaluated doses, with a dose-dependent trend. A weight-adapted cosyntropin dose of 0.2 µg in obesity produces a similar response to the one observed in individuals without obesity. The 1 µg ACTH test falls short on stimulating the cortisol adrenal response in individuals with obesity.


  • Intensive vs. conventional blood pressure goals in older patients with type 2 diabetes: a systematic review and meta-analysis

    by Rene Rodriguez-Gutierrez, Andrea Flores-Rodríguez, Karina Raygoza-Cortez, Mariana Garcia-Leal, Sofía Mariño-Velasco, Hiram H. Plata-Huerta, Melissa Sáenz-Flores, Luz A. Ramirez-Garcia, Amanda Rojo-Garza, Spyridoula Maraka, et al.

    Purpose Assess the effect of intensive vs conventional blood pressure goals on patient-important outcomes in older adults with type 2 diabetes. Methods A comprehensive search was performed using electronic databases. Randomized controlled trials comparing intensive vs conventional blood pressure goals in adults over 60 years of age with type 2 diabetes were included. Events were evaluated using a modified Mantel-Haenszel meta-analysis with Peto’s method. Study selection and data extraction were performed independently and in duplicate. Results Seven trials were included. A 19% risk reduction (OR 0.81; 95% CI 0.69–0.95; I2 = 8%; p = 0.35) in the occurrence of major adverse cardiovascular events (MACE) and 37% risk reduction (OR 0.63; 95% CI 0.51–0.79; I2 = 0%; p = 0.56) in the occurrence of fatal or non-fatal stroke was documented in the intensive treatment group. There were no differences in the occurrence of all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and peripheral vascular disease. Data regarding treatment adverse effects and microvascular outcomes was scarce. Conclusions Intensive blood pressure goals in older patients with diabetes were associated with a lower risk of stroke and MACE, but not with all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and peripheral vascular disease.


  • Open Access

    Research barriers in the Global South: Mexico

    by Alejandro Quiroga-Garza, Andrea N Garza-Cisneros, Rodrigo E Elizondo-Omaña, Jose F Vilchez-Cavazos, Roberto Montes De-Oca-Luna, Eliud Villarreal-Silva, Santos Guzman-Lopez, Jose G Gonzalez-Gonzalez

    The term Global South is used to denominate the regions outside Europe and North America (Latin America, Africa, Asia, and Oceania), economically, politically, or culturally marginalized [1,2]. One of the limitations of the Global South is the health inequities. There is a shortage of health care professionals, researchers, and economic resources in low- and middle-income […]